search
Back to results

Treatment for Cellulite Appearance

Primary Purpose

Cellulite

Status
Active
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Sofwave
Sponsored by
Sofwave Medical LTD
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cellulite focused on measuring upper thigh, buttock, skin laxity

Eligibility Criteria

18 Years - 60 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  1. Healthy female subjects > 18 years of age and < 60 years of age
  2. Not pregnant or lactating and must be either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment (i.e., oral contraceptives, contraceptive implant, barrier methods with spermicide) or abstinence.
  3. Have visible cellulite in the upper thigh and/or buttock areas.
  4. Seeking treatment of cellulite in the upper thigh and/or buttock areas.
  5. Stable weight nominally ±5% for at least past 6 months
  6. Subject agrees to maintain her weight (i.e., within 5% of total body weight) by not making any major changes in their diet or exercise routine during the study course.
  7. Subject did not undergo invasive or energy-based cellulite treatments (liposuction, subcision, RF, laser, ESWT, etc.) for the prior 12 months.
  8. Subject did not use topical based cellulite treatments for prior 6 months and will not use during the trial (except for the study related procedures)
  9. Subject agrees not to undergo any other cellulite treatments for a period of 6 months following Sofwave treatment
  10. Willing to have photographs of the treated areas. Agree for de-identified study images to be used in evaluations, publications, and presentations.
  11. Able and willing to comply with all visits, treatments and evaluations schedules and requirements.
  12. Able to understand and provide written Informed Consent.

Exclusion Criteria:

  1. Pregnant or planning to become pregnant during the duration of the study, having given birth less than 3 months ago, and/or breast feeding
  2. Currently heavy smoker or has history of heavy smoking (25 cigarettes per day or more) in past 10 years
  3. BMI>=30kg/m2
  4. Non-stable weight nominally ±5% for at least past 6 months
  5. Currently taking or has taken diet pills or weight control supplements within the past month
  6. History of severe migraine tendency
  7. History of Epileptic seizures
  8. History of chronic drug or alcohol abuse
  9. History of coagulopathy(ies) and/or on anticoagulant medication
  10. History of bleeding disorder or is taking any medication that in the investigator's opinion may increase the subject's risk of bruising
  11. Medical disorder that would hinder the wound healing or immune response (such as blood disorder, inflammatory disease, etc.)
  12. Active implanted device such as a pacemaker, defibrillator, cochlear implants, nerve/brain stimulators or drug delivery system
  13. Known allergy to lidocaine or epinephrine or antibiotics
  14. Active malignancy or history of malignancy in the past 5 years
  15. Suffering from significant concurrent illness, such as cardiac disorders, diabetes (type I or II), lupus, porphyria, or pertinent neurological disorders (i.e. any disease state that in the opinion of the investigator may interfere with the anesthesia, treatment, or healing process)
  16. History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications
  17. Suffering from hormonal imbalance, whether related to thyroid, pituitary, or androgen
  18. History of significant lymphatic drainage problems
  19. History of epidermal or dermal disorders (particularly involving collagen or microvascularity), including collagen vascular disease or vasculitic disorders.
  20. Skin disorders (skin infections or rashes, extensive scarring, psoriasis, etc.) in the treatment area.
  21. Severe solar elastosis on the intended to treat area.
  22. Significant scarring, atrophic scars in the area to be treated, or has a history of atrophic scars or keloids or prone to bruising
  23. Tattoo or former tattoo at or near treatment area
  24. Presence of an implant (metal or plastic) in or adjacent to area of intended treatment (vascular stent, or implants in the hips, knees, etc)
  25. Inability to understand the protocol or to give informed consent
  26. On-going use of psychiatric medication
  27. Unable or unwilling to comply with the study requirements and procedures
  28. Unwilling to have research photos taken of treatment areas
  29. Currently enrolled in a clinical study of any other unapproved investigational drug or device
  30. Any other condition that would, in the professional opinion of the investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject

Sites / Locations

  • Laser & Skin Surgery Center of Northern California
  • UnionDerm
  • Laser & Skin Surgery Center of New York®
  • Dermatology, Laser & Vein Specialists of the Carolinas

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Cellulite

Arm Description

Outcomes

Primary Outcome Measures

Rate of improvement in the appearance of cellulite on the upper thigh/buttock area
following Sofwave treatments based on 6 points simplified Cellulite Severity Scale (CSS), as evaluated by independent masked reviewers.

Secondary Outcome Measures

Full Information

First Posted
April 27, 2022
Last Updated
May 2, 2023
Sponsor
Sofwave Medical LTD
search

1. Study Identification

Unique Protocol Identification Number
NCT05358847
Brief Title
Treatment for Cellulite Appearance
Official Title
Safety and Efficacy of Sofwave Treatment for Improvement of Cellulite Appearance
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
November 21, 2021 (Actual)
Primary Completion Date
March 1, 2023 (Actual)
Study Completion Date
March 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sofwave Medical LTD

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Open-label, non-randomized, prospective, multi-center, self-controlled clinical study with masked evaluation.
Detailed Description
Eligible patients will receive 2 treatments (4-6 weeks apart) on one side (right or left) of the lateral/ posterior upper thigh / buttocks using Sofwave System. Treatment may be administered after the enrollment and screening at the first visit, or it may occur later following the enrollment and screening activities based on site scheduling availabilities. All patients will return to the clinic for one follow up visits at 3 months ± 3 weeks post last treatment (FU1). Optionally, additional follow-up visit will be conducted 6 (± 4 weeks) months following end of treatment (FU2). Methodology described in the protocol to evaluate efficacy and safety of treatments will be carried out at each visit at the clinic.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cellulite
Keywords
upper thigh, buttock, skin laxity

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
69 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Cellulite
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
Sofwave
Other Intervention Name(s)
SUPERB
Intervention Description
The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
Primary Outcome Measure Information:
Title
Rate of improvement in the appearance of cellulite on the upper thigh/buttock area
Description
following Sofwave treatments based on 6 points simplified Cellulite Severity Scale (CSS), as evaluated by independent masked reviewers.
Time Frame
3 months post treatment follow-up visit.

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy female subjects > 18 years of age and < 60 years of age Not pregnant or lactating and must be either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment (i.e., oral contraceptives, contraceptive implant, barrier methods with spermicide) or abstinence. Have visible cellulite in the upper thigh and/or buttock areas. Seeking treatment of cellulite in the upper thigh and/or buttock areas. Stable weight nominally ±5% for at least past 6 months Subject agrees to maintain her weight (i.e., within 5% of total body weight) by not making any major changes in their diet or exercise routine during the study course. Subject did not undergo invasive or energy-based cellulite treatments (liposuction, subcision, RF, laser, ESWT, etc.) for the prior 12 months. Subject did not use topical based cellulite treatments for prior 6 months and will not use during the trial (except for the study related procedures) Subject agrees not to undergo any other cellulite treatments for a period of 6 months following Sofwave treatment Willing to have photographs of the treated areas. Agree for de-identified study images to be used in evaluations, publications, and presentations. Able and willing to comply with all visits, treatments and evaluations schedules and requirements. Able to understand and provide written Informed Consent. Exclusion Criteria: Pregnant or planning to become pregnant during the duration of the study, having given birth less than 3 months ago, and/or breast feeding Currently heavy smoker or has history of heavy smoking (25 cigarettes per day or more) in past 10 years BMI>=30kg/m2 Non-stable weight nominally ±5% for at least past 6 months Currently taking or has taken diet pills or weight control supplements within the past month History of severe migraine tendency History of Epileptic seizures History of chronic drug or alcohol abuse History of coagulopathy(ies) and/or on anticoagulant medication History of bleeding disorder or is taking any medication that in the investigator's opinion may increase the subject's risk of bruising Medical disorder that would hinder the wound healing or immune response (such as blood disorder, inflammatory disease, etc.) Active implanted device such as a pacemaker, defibrillator, cochlear implants, nerve/brain stimulators or drug delivery system Known allergy to lidocaine or epinephrine or antibiotics Active malignancy or history of malignancy in the past 5 years Suffering from significant concurrent illness, such as cardiac disorders, diabetes (type I or II), lupus, porphyria, or pertinent neurological disorders (i.e. any disease state that in the opinion of the investigator may interfere with the anesthesia, treatment, or healing process) History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications Suffering from hormonal imbalance, whether related to thyroid, pituitary, or androgen History of significant lymphatic drainage problems History of epidermal or dermal disorders (particularly involving collagen or microvascularity), including collagen vascular disease or vasculitic disorders. Skin disorders (skin infections or rashes, extensive scarring, psoriasis, etc.) in the treatment area. Severe solar elastosis on the intended to treat area. Significant scarring, atrophic scars in the area to be treated, or has a history of atrophic scars or keloids or prone to bruising Tattoo or former tattoo at or near treatment area Presence of an implant (metal or plastic) in or adjacent to area of intended treatment (vascular stent, or implants in the hips, knees, etc) Inability to understand the protocol or to give informed consent On-going use of psychiatric medication Unable or unwilling to comply with the study requirements and procedures Unwilling to have research photos taken of treatment areas Currently enrolled in a clinical study of any other unapproved investigational drug or device Any other condition that would, in the professional opinion of the investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject
Facility Information:
Facility Name
Laser & Skin Surgery Center of Northern California
City
Sacramento
State/Province
California
ZIP/Postal Code
95816
Country
United States
Facility Name
UnionDerm
City
New York
State/Province
New York
ZIP/Postal Code
10003
Country
United States
Facility Name
Laser & Skin Surgery Center of New York®
City
New York
State/Province
New York
ZIP/Postal Code
10016
Country
United States
Facility Name
Dermatology, Laser & Vein Specialists of the Carolinas
City
Charlotte
State/Province
North Carolina
ZIP/Postal Code
28207
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Treatment for Cellulite Appearance

We'll reach out to this number within 24 hrs